Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 23, 2009, Pages 9403-9408

  Dinoso, J B ^a   Kim, S Y ^a   Wiegand, A M ^b   Palmer, S E ^b,h   Gange, S J ^c   Cranmer, L ^a   O'Shea, A ^d   Callender, M ^a   Spivak, A ^a   Brennan, T ^a   Kearney, M F ^b   Proschan, M A ^e   Mican, J M ^e   Rehm, C A ^e   Coffin, J M ^b,f   Mellors, J W ^g   Siliciano, R F ^a   Maldarelli, F ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^h KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antiretroviral drug intensification; HIV 1 persistance; Viral reservoir

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; TENOFOVIR DISOPROXIL; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG POTENCY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHUMAN; PATIENT COMPLIANCE; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIREMIA; VIRUS REPLICATION; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV-1; HUMANS; PROSPECTIVE STUDIES; VIREMIA; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 67249121143     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0903107106     Document Type: Article

References (54)

1. Ho DD, et al. (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
2. Wei X, et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.
3. Mellors JW, et al. (1996) Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167-1170. (Pubitemid 26001148)
4. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996) HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586. (Pubitemid 26097216)
5. Gulick RM, et al. (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337:734-739. (Pubitemid 27417972)
6. Hammer SM, et al. (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS clinical trials group 320 study team. N Engl J Med 337:725-733. (Pubitemid 27417971)
7. Perelson AS, et al. (1997) Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387:188-191. (Pubitemid 27209434)
8. Chun TW, et al. (1995) In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency. Nat Med 1:1284-1290.
9. Chun TW, et al. (1997) Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183-188. (Pubitemid 27209433)
10. Chun TW, et al. (1997) Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 94:13193-13197. (Pubitemid 27518498)
11. Finzi D, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300. (Pubitemid 27495742)
12. Wong JK, et al. (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295. (Pubitemid 27495741)
13. Finzi D, et al. (1999) Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5:512-517. (Pubitemid 29220209)
14. Siliciano JD, et al. (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9:727-728. (Pubitemid 36749221)
15. Strain MC, et al. (2003) Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: Intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci USA 100:4819-4824. (Pubitemid 36457812)
16. Dornadula G, et al. (1999) Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. J Am Med Assoc 282:1627-1632. (Pubitemid 29513968)
17. Palmer S, et al. (2003) New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 41:4531-4536. (Pubitemid 37259753)
18. Maldarelli F, et al. (2007) ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 3:e46. (Pubitemid 46683483)
19. Palmer S, et al. (2008) Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 105:3879-3884. (Pubitemid 351723493)
20. Paterson DL, et al. (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133:21-30. (Pubitemid 30432540)
21. Maggiolo F, et al. (2007) Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials 8:282-292. (Pubitemid 350099562)
22. Nachega JB, et al. (2007) Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 146:564-573. (Pubitemid 351650537)
23. Joos B, et al. (2008) HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci USA 105:16725-16730.
24. Hermankova M, et al. (2001) HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/mL receiving combination therapy. J Am Med Assoc 286:196-207. (Pubitemid 32640851)
25. Persaud D, et al. (2004) Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol 78:968-979. (Pubitemid 38067618)
26. Bailey JR, et al. (2006) Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 80:6441-6457. (Pubitemid 43927447)
27. Havlir DV, et al. (2003) Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 77:11212-11219. (Pubitemid 37204311)
28. Ramratnam B, et al. (2004) Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr 35:33-37. (Pubitemid 38044779)
29. Hammer SM, et al. (2008) Antiretroviral treatment of adult HIV infection: 2008 recommendations of the international AIDS society-USA panel. J Am Med Assoc 300:555-570.
30. Panel on Antiretroviral Guidelines for Adults and Adolescents (2008) Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (Department of Health and Human Services, Washington, DC), pp 1-128.
31. Shen L, et al. (2008) Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 14:762-766. (Pubitemid 351951518)
32. Nettles RE, et al. (2005) Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. J Am Med Assoc 293:817-829. (Pubitemid 40250365)
33. Colonno R, et al. (2004) Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis 189:1802-1810. (Pubitemid 38657216)
34. Kozal MJ, et al. (1996) Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 2:753-759. (Pubitemid 26225090)
35. Ramratnam B, et al. (2000) The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 6:82-85. (Pubitemid 30048531)
36. Peeters MF, et al. (1995) Comparison of human immunodeficiency virus biological phenotypes isolated from cerebrospinal fluid and peripheral blood. J Med Virol 47:92-96.
37. Clements JE, et al. (2005) The central nervous system is a viral reservoir in simian immunodeficiency virus-infected macaques on combined antiretroviral therapy: A model for human immunodeficiency virus patients on highly active antiretroviral therapy. J Neurovirol 11:180-189. (Pubitemid 40852425)
38. Quayle AJ, Xu C, Mayer KH, Anderson DJ (1997) T lymphocytes and macrophages, but not motile spermatozoa, are a significant source of human immunodeficiency virus in semen. J Infect Dis 176:960-968. (Pubitemid 27411038)
39. Foudraine NA, et al. (1998) Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 351:1547-1551. (Pubitemid 28230890)
40. Aweeka F, et al. (1999) Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex. J Acquir Immune Defic Syndr Hum Retrovirol 20:39-43. (Pubitemid 29045468)
41. Kravcik S, et al. (1999) Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir. J Acquir Immune Defic Syndr 21:371-375. (Pubitemid 29383998)
42. Tashima KT, et al. (1999) Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J Infect Dis 180:862-864. (Pubitemid 29411379)
43. Taylor S, et al. (2001) Penetration of efavirenz into the male genital tract: Drug concentrations and antiviral activity in semen and blood of HIV-1-infected men. AIDS 15:2051-2053. (Pubitemid 32980652)
44. van Leeuwen E, et al. (2007) Penetration of atazanavir in seminal plasma of men infected with human immunodeficiency virus type 1. Antimicrob Agents Chemother 51:335-337. (Pubitemid 46047724)
45. Letendre S, et al. (2008) Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65:65-70.
46. Best BM, et al. (2009) Low atazanavir concentrations in cerebrospinal fluid. AIDS 23:83-87.
47. Price RW & Spudich S (2008) Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis 197(Suppl 3):S294-S306. (Pubitemid 351717319)
48. Kalvass JC, Maurer TS, Pollack GM (2007) Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: Comparison of unbound concentration ratios to in vivo P-glycoprotein efflux ratios. Drug Metab Dispos 35, 660-666. (Pubitemid 46513270)
49. Wilkin TJ, et al. (2009) Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: Final 48-week clinical and virologic outcomes. J Infect Dis 199:866-871.
50. Sun R, et al. (1998) Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 36:2964-2969. (Pubitemid 28429422)
51. Lamotte C, Peytavin G, Farinotti R (1999) Determination of nelfinavir, a potent HIV protease inhibitor, and its active metabolite M8 in human plasma by high-performance liquid chromatography with photodiode-array detection. J Chromatogr B Biomed Sci Appl 735:159-170.
52. Nettles RE, et al. (2006) Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 42:1189-1196.
53. Hughes JP (1999) Mixed effects models with censored data with application to HIV RNA levels. Biometrics 55:625-629. (Pubitemid 29302594)
54. Thiebaut R, Jacqmin-Gadda H (2004) Mixed models for longitudinal left-censored repeated measures. Comput Methods Programs Biomed 74:255-260. (Pubitemid 38591637)